What is the Columbia Suicide Severity Rating Scale (C-SSRS)?

The C-SSRS is a structured suicide risk assessment tool developed by Posner et al. at Columbia University. It assesses five levels of suicidal ideation (types 1-5) and four categories of suicidal behavior (actual attempt, interrupted attempt, aborted attempt, preparatory acts). It is endorsed by the FDA, CDC, WHO, and SAMHSA as the gold standard suicide risk assessment instrument.

Why is C-SSRS required in clinical trials?

The FDA's 2012 guidance on suicidal ideation and behavior in clinical trials requires sponsors to prospectively assess and report treatment-emergent suicidal events using the C-SSRS. This requirement applies to all CNS drugs and many other drug classes. The C-SSRS provides standardized, reproducible behavioral definitions enabling pooled analyses and regulatory safety evaluation across trial sites.

What are the crisis resources for suicidal patients?

In the US: 988 Suicide and Crisis Lifeline (call or text 988), available 24/7 in English and Spanish. Crisis Text Line (text HOME to 741741). Veterans Crisis Line (call 988, press 1; text 838255). International Association for Suicide Prevention maintains a directory of crisis centers worldwide at https://www.iasp.info/resources/Crisis_Centres/. These resources should be included in all written safety plans.

Is prior suicide attempt the strongest risk factor?

Yes. A history of prior suicide attempt is the single strongest predictor of future suicide attempt, increasing risk approximately 30-fold compared to individuals with no attempt history. Attempt method lethality, degree of planning, and whether the patient is glad to have survived are important nuances. All prior attempts — regardless of apparent medical seriousness — should be carefully documented including method, circumstances, rescue factors, and the patient's retrospective view of the attempt.

What is the brief version of C-SSRS?

The C-SSRS screener version consists of 6 yes/no questions arranged hierarchically. It can be administered in 1-2 minutes and is appropriate for non-clinical administrators after brief training. The full C-SSRS clinical version includes detailed intensity ratings for ideation (frequency, duration, controllability, deterrents, reasons for ideation) and is administered by trained mental health professionals. The 'since last visit' version is designed for serial monitoring in outpatient care.

Can the C-SSRS be self-administered?

The standard C-SSRS is designed for clinician administration with direct patient interaction, allowing probing questions and observation of responses. However, a self-report version of the C-SSRS exists and has been validated in research contexts, including electronic administration in clinical trials. The self-report version should be followed by clinician review of positive responses. The screener version administered by a trained non-clinical person is considered adequate for initial triage in non-clinical settings.

What is the sensitivity and specificity of C-SSRS for future suicide attempt?

In Posner et al. (2011) validation data, ideation types 4-5 had sensitivity 89% and specificity 75% for prospective suicide attempt. The C-SSRS ideation score independently predicted future attempts after controlling for prior attempt history. The screener's predictive validity has been demonstrated across multiple populations including emergency department patients, inpatient psychiatric patients, and clinical trial participants.

Online Medical Tools — C-SSRS Screener

Printed on 8/14/2026

For informational purposes only. This is not medical advice.

Mental Health

C-SSRS Screener

The Columbia Suicide Severity Rating Scale (C-SSRS) screener is a brief, structured assessment tool designed to identify the presence and severity of suicidal ideation and behavior. It uses six yes/no questions arranged in a hierarchical order of increasing severity, from passive wish for death to active suicidal ideation with specific plan and intent. The C-SSRS is endorsed by the FDA, CDC, WHO, and numerous clinical guidelines as a standard suicide risk screening tool. It is used in emergency departments, primary care, schools, military settings, and research worldwide.

Formula: Risk level based on highest 'Yes' response. Q1-2: ideation. Q3-5: ideation with method/intent/plan. Q6: suicidal behavior.

1. Wish to be dead

2. Non-specific active suicidal thoughts

3. Active suicidal ideation with any methods (not plan) without intent to act

4. Active suicidal ideation with some intent to act, without specific plan

5. Active suicidal ideation with specific plan and intent

6. Any suicidal behavior (lifetime)

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Assess 5 Ideation Types in the Past Month

The C-SSRS screener assesses five levels of suicidal ideation in a hierarchical structure. Type 1: passive wish to be dead ('I wish I could go to sleep and not wake up'). Type 2: non-specific suicidal ideation ('I have thoughts of killing myself'). Type 3: suicidal ideation with a method but no intent or plan. Type 4: suicidal ideation with some intention to act. Type 5: suicidal ideation with a specific plan and intent to carry it out. Each type builds on the previous — clinicians identify the highest type present and document it as the current ideation level.

Assess Suicidal Behavior (Lifetime and Past 3 Months)

Beyond ideation, the C-SSRS assesses four categories of suicidal behavior: actual suicide attempt (self-injurious act with intent to die), interrupted attempt (stopped by external circumstance before beginning), aborted attempt (stopped by the individual before beginning), and preparatory acts (gathering means, writing a note, giving away possessions). Behaviors are assessed both over the individual's lifetime and in the past 3 months, as recent behavior carries greater acute risk weight.

Determine Risk Level and Clinical Action Required

Any ideation type 4 or 5, or any suicidal behavior in the past 3 months, constitutes high acute risk and requires immediate safety assessment and likely psychiatric evaluation. Ideation types 1-3 without behavior represent lower but clinically meaningful risk requiring close monitoring, safety planning, and follow-up. No ideation and no behavior in the past 3 months indicates low current risk. Document both the risk level and protective factors, access to lethal means, and any acute stressors identified during assessment.

Who Uses the C-SSRS Screener

Emergency Psychiatric Evaluation Triage

Emergency Psychiatrists

The C-SSRS is the standard suicide risk assessment tool in emergency psychiatric settings. Its hierarchical structure rapidly distinguishes passive death wishes from active suicidal ideation with plan and intent, enabling triage decisions about disposition (discharge, voluntary admission, involuntary hold).

Outpatient Mental Health Ongoing Risk Monitoring

Therapists and Psychiatrists

In outpatient mental health care, the 'since last visit' version of C-SSRS enables clinicians to systematically track suicidal ideation between sessions. Any escalation from type 1-2 to type 4-5 between visits signals urgent need for safety reassessment.

Clinical Trial Suicide Safety Monitoring

Clinical Researchers

The FDA's 2012 guidance recommends C-SSRS for all CNS drug clinical trials to monitor treatment-emergent suicidal ideation and behavior. Its standardized scoring enables cross-trial comparisons and regulatory safety dossier preparation.

Acute Inpatient Psychiatric Assessment

Inpatient Psychiatric Teams

On inpatient psychiatry units, the C-SSRS is administered at admission and before discharge to document risk trajectory. A patient admitted with ideation type 5 who discharges with type 1-2 demonstrates measurable improvement that supports the clinical decision for discharge.

Primary Care Patients with Depression

Primary Care Physicians

Primary care providers frequently encounter patients with depression who may harbor suicidal ideation. The screener version of C-SSRS enables non-psychiatric clinicians to conduct a structured, documented suicide risk assessment and determine when mental health referral is urgent.

FDA-Required Safety Monitoring in Antidepressant Trials

Pharmaceutical Researchers

Black-box warnings on antidepressants require monitoring of treatment-emergent suicidal ideation, particularly in pediatric and young adult populations. C-SSRS provides the standardized behavioral endpoint that satisfies FDA post-marketing safety requirements.

Pro Tips

C-SSRS Is the Gold Standard Endorsed by FDA, CDC, and WHO

The Columbia Suicide Severity Rating Scale is recognized by the FDA, CDC, WHO, and SAMHSA as the preferred suicide risk assessment tool for both clinical practice and research. The FDA's 2012 guidance explicitly recommends C-SSRS for all clinical trials involving CNS drugs, making it the most widely required suicide assessment tool in pharmaceutical research.

Ideation Types 4-5 Always Require Immediate Intervention

C-SSRS ideation types 4 and 5 represent active suicidal ideation with intent — where the individual has some intention (type 4) or a specific plan and intent (type 5) to act on suicidal thoughts. These always require immediate intervention: safety planning, means restriction counseling, and determination of appropriate level of care. Do not discharge or end a session without a documented safety plan when types 4-5 are present.

Prior Attempts Are the Strongest Predictor of Future Attempt

A history of prior suicide attempt increases the risk of future attempt approximately 30-fold compared to individuals with no attempt history. Always ask about lifetime attempts (Question 6 on the screener) and document attempt method, lethality, and rescue circumstances. Prior attempts with high medical lethality or low rescue likelihood carry the highest future risk.

Lethal Means Counseling Is a Critical Evidence-Based Intervention

Means restriction — particularly firearm safety and secure storage of medications — is one of the strongest evidence-based suicide prevention interventions. A patient with suicidal ideation who has access to a loaded firearm at home is at substantially higher acute risk than one without access. Ask about and document access to all lethal means, and involve family members in means restriction counseling when possible.

Safety Planning Reduces Suicide Attempts in High-Risk Patients

The Stanley-Brown Safety Planning Intervention (SPI) combines C-SSRS-based risk stratification with a personalized written safety plan identifying warning signs, coping strategies, social supports, and crisis resources. Evidence from multiple studies shows that SPI combined with C-SSRS-guided monitoring significantly reduces suicide attempts in high-risk populations compared to treatment as usual.

Document Clinical Context, Not Just the Score

The C-SSRS score alone is not sufficient documentation. Document the clinical context that informed your risk assessment: access to lethal means, protective factors (children, religious beliefs, therapeutic relationship), acute stressors (recent loss, legal problems, relationship crisis), substance use status, and any prior attempts with method and lethality. This narrative context is as important as the ideation type for medicolegal documentation.

Use the Version Appropriate for Your Clinical Setting

The C-SSRS exists in multiple validated versions for different settings: the screener (6 questions, rapid administration), the full clinical version (detailed intensity ratings), the 'since last visit' version (for serial monitoring in outpatient care), and the lifetime/recent version (for initial assessments). Using the version appropriate for your context improves both clinical efficiency and measurement accuracy.

Crisis Resources: 988 Lifeline and Crisis Text Line

In the US, the 988 Suicide and Crisis Lifeline (call or text 988) provides 24/7 free and confidential support. The Crisis Text Line (text HOME to 741741) is available for those who prefer text-based communication. These resources should be provided to any patient with positive C-SSRS ideation and included in written safety plans.

Inpatient Admission Criteria for High C-SSRS Risk

Inpatient psychiatric admission is generally indicated when a patient has: active plan with access to means, inability to commit to a safety plan, active intoxication, lack of social support, history of high-lethality prior attempt, or imminent decompensation in mental status. A high C-SSRS ideation type alone (without these contextual factors) may be managed safely on an outpatient basis with intensive safety planning and close follow-up.

Differentiate Chronic SI in Personality Disorders From Acute Escalation

Patients with borderline personality disorder (BPD) frequently experience chronic passive suicidal ideation (types 1-2) as a baseline feature of their illness. The clinical priority is identifying acute escalation above the individual's baseline — from passive to active ideation, emergence of a plan, or new high-lethality behavior. Dialectical behavior therapy (DBT) is the evidence-based treatment for reducing suicidal behavior in BPD.

Common Questions About Your Results

Passive suicidal ideation (C-SSRS types 1-2) involves wishes to be dead or general thoughts of killing oneself without a specific method or intent to act. Active suicidal ideation (C-SSRS types 4-5) involves thinking about suicide with some intention to act (type 4) or having a specific plan with intent to carry it out (type 5). Type 3 is an intermediate state — ideation with a method in mind but without intent. The clinical urgency escalates from type 1 to type 5, with types 4-5 always requiring immediate intervention.

Access to lethal means — particularly firearms and stockpiled medications — is a major modifiable risk factor for suicide attempt completion. The interval between suicidal impulse and attempt is often very short, and the method's availability at the moment of crisis largely determines outcome. Studies show that states with higher firearm ownership rates have higher suicide rates, and that household firearm removal or secure storage significantly reduces risk. Always ask about access to firearms and medications and counsel on means restriction.

Patients with borderline personality disorder often experience passive suicidal ideation (types 1-2) as a chronic baseline feature. The critical clinical question is not whether ideation is present, but whether it has escalated above the individual's personal baseline. Ask about the frequency and intensity of current ideation compared to typical, whether a new method or plan has emerged, and whether there are acute precipitants (relationship loss, legal crisis, substance use). Escalation above baseline warrants the same urgent clinical response as new-onset active ideation in other patients.

No. The C-SSRS screener cannot rule out suicide risk. Individuals who are determined to conceal suicidal ideation may deny symptoms on any structured instrument. A negative screen should reduce clinical concern but does not eliminate it. Clinicians must integrate the screener result with clinical observation, collateral history from family, knowledge of the patient's psychiatric history, and any contextual risk factors. If clinical judgment suggests elevated risk despite a negative screen, further evaluation is warranted.

Documentation should include: the C-SSRS ideation type (1-5) or behavior category present, the specific ideation content and any plan or method identified, access to lethal means and any means restriction counseling provided, protective factors and acute stressors identified, the clinical risk formulation (imminent, near-term, or chronic risk), any safety plan completed, the level of care disposition, and follow-up arrangements. Thorough documentation protects the patient through clear care continuity and protects the clinician in medicolegal reviews.

Evidence-Based Methodology

Columbia Suicide Severity Rating Scale (C-SSRS) developed by Posner et al. (Am J Psychiatry 2011) from patients in psychiatric research. Sensitivity 89%, specificity 75% for prospective suicide attempt at ideation type 4-5. FDA 2012 guidance recommends C-SSRS for all clinical trials involving CNS drugs. C-SSRS has been validated in 50+ languages. SAMHSA recommends C-SSRS for clinical and research use. Training available at cssrs.columbia.edu. Stanley-Brown Safety Planning Intervention evidence: Stanley and Brown (J Clin Psychol 2012).

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

The C-SSRS screener result is determined by the highest-numbered question answered 'Yes,' reflecting the most severe level of suicidal ideation or behavior endorsed. If only Question 1 is positive (wish to be dead), this indicates passive suicidal ideation and warrants further monitoring and clinical follow-up. If Question 2 is positive (thoughts of killing yourself), active suicidal ideation is present and requires a more thorough risk assessment.

Positive responses to Questions 3 through 5 indicate progressively more severe active suicidal ideation: Question 3 positive means the person has thought about a method, Question 4 positive means there is some intent to act, and Question 5 positive means there is a specific plan with intent. These escalating levels of ideation require increasingly urgent clinical intervention, safety planning, and consideration of higher levels of care.

A positive response to Question 6 indicates suicidal behavior — the person has made a prior attempt, started to carry out a plan, or made preparations. This is the highest risk category on the screener and warrants immediate safety assessment, means restriction counseling, and determination of the appropriate level of care. Any positive response on the C-SSRS should trigger a comprehensive clinical evaluation and documentation of the safety plan.

When to Use This Tool

The C-SSRS screener should be used whenever there is a clinical need to assess for suicidal ideation and behavior. It is appropriate for universal screening in emergency departments, inpatient psychiatric admissions, primary care visits where depression or risk factors are identified, and as part of intake assessments in mental health settings. Many health systems now mandate universal suicide screening using the C-SSRS or similar validated tools.

This tool is also indicated when a patient presents with depression, hopelessness, recent psychosocial stressors, substance use, or any clinical concern for self-harm. It can be used by non-clinical staff after brief training, making it suitable for schools, crisis hotlines, military settings, and community organizations. The C-SSRS screener is designed for rapid administration and can be completed in one to two minutes.

Limitations

The C-SSRS screener is a brief screening version and does not capture the full detail of the complete C-SSRS clinical assessment, which includes intensity ratings for ideation (frequency, duration, controllability, deterrents, reasons) and detailed behavior assessment. A positive screener should prompt a more comprehensive evaluation by a qualified clinician.

Like all suicide risk assessment tools, the C-SSRS cannot predict with certainty whether an individual will attempt suicide. Suicide risk is dynamic and can change rapidly based on circumstances, access to means, and protective factors. A negative screen does not eliminate risk, and clinical judgment must always be applied alongside structured screening.

The screener relies on honest self-disclosure, and individuals who are determined to conceal suicidal ideation may deny symptoms. Cultural factors, stigma, and the clinical environment can all influence willingness to disclose. The C-SSRS should be administered in a private, supportive setting and should be considered one component of a comprehensive risk assessment rather than a standalone decision-making tool.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools

Mental Health

PHQ-9

Free PHQ-9 depression screening questionnaire. Take the Patient Health Questionnaire-9 to assess depression severity with instant scoring and interpretation. Also screen for anxiety with [GAD-7](/tools/gad7).

Open Mental Health

GAD-7

Free GAD-7 anxiety screening questionnaire. Take the Generalized Anxiety Disorder 7-item scale to assess anxiety severity with instant scoring and interpretation. Also screen for depression with [PHQ-9](/tools/phq9).

Open Mental Health

PHQ-2

Quick two-question depression screen using the PHQ-2. A score of 3 or higher suggests further evaluation with the full [PHQ-9](/tools/phq9).

Open

Frequently Asked Questions

Risk is determined by the highest ideation type present and any behavior in the past 3 months. Ideation types 1-2 = passive or non-specific ideation requiring monitoring. Ideation types 3-5 = escalating active ideation requiring increasingly urgent intervention. Any behavior (actual/interrupted/aborted attempt, preparatory acts) in the past 3 months = high acute risk requiring immediate safety assessment.

The C-SSRS is a clinician-administered structured interview assessing current and past suicidal ideation and behavior with precise type-based scoring. The SBQ-R is a brief 4-item self-report questionnaire. The C-SSRS is preferred for clinical settings and FDA-required research; the SBQ-R is more practical for self-administered screening in research contexts. Both have evidence for predictive validity for future suicide attempts.

High acute risk is indicated by: ideation type 4 or 5 (active ideation with intent), any suicidal behavior in the past 3 months (actual/interrupted/aborted attempt, preparatory acts), or combination of ideation type 3 with multiple additional risk factors (access to means, prior attempts, acute stressors, intoxication, lack of social support). High risk requires immediate safety assessment and determination of appropriate level of care.

Safety planning (Stanley-Brown Safety Planning Intervention) is an evidence-based structured intervention combining C-SSRS risk assessment with a personalized written plan including: personal warning signs, individual coping strategies, social supports to contact, crisis resources (988 Lifeline, Crisis Text Line), and means restriction. Safety planning reduces suicide attempts significantly compared to treatment as usual and is recommended for all patients with elevated C-SSRS risk.

Online Medical Tools — C-SSRS Screener

C-SSRS Screener

How It Works

Assess 5 Ideation Types in the Past Month

Assess Suicidal Behavior (Lifetime and Past 3 Months)

Determine Risk Level and Clinical Action Required

Who Uses the C-SSRS Screener

Emergency Psychiatric Evaluation Triage

Outpatient Mental Health Ongoing Risk Monitoring

Clinical Trial Suicide Safety Monitoring

Acute Inpatient Psychiatric Assessment

Primary Care Patients with Depression

FDA-Required Safety Monitoring in Antidepressant Trials

Pro Tips

C-SSRS Is the Gold Standard Endorsed by FDA, CDC, and WHO

Ideation Types 4-5 Always Require Immediate Intervention

Prior Attempts Are the Strongest Predictor of Future Attempt

Lethal Means Counseling Is a Critical Evidence-Based Intervention

Safety Planning Reduces Suicide Attempts in High-Risk Patients

Document Clinical Context, Not Just the Score

Use the Version Appropriate for Your Clinical Setting

Crisis Resources: 988 Lifeline and Crisis Text Line

Inpatient Admission Criteria for High C-SSRS Risk

Differentiate Chronic SI in Personality Disorders From Acute Escalation

Common Questions About Your Results

Evidence-Based Methodology

Clinical Content Trust

How to Interpret Your Result

When to Use This Tool

Limitations

Changelog

Related Tools

PHQ-9

GAD-7

PHQ-2

Further Reading

Mental Health Screening Guide: Depression, Anxiety, Substance Use, and Cognitive Assessment

Frequently Asked Questions